SCIENTIFIC ADVISOR

Dr. Rob Allen has worked in both large and small pharma and more recently worked as CMO for 3 different start-up companies. He also has a broad range of regulatory submission experience, including INDs, NDAs, and sNDAs.

At present, Dr. Allen is VP in the Neuroscience / Medical Science and Strategy Division of PPD / TF.  In this role, Dr. Allen provides medical and clinical trial / program support for all Neuroscience initiatives.  His historical focus has been in pain with a most notable role as Medical Director for the development of pregabalin / Lyrica.  Since joining PPD / TF, Dr Allen has been involved in programs for Acute and Chronic Pain, Epilepsy, AD, Stroke, and MDD initiatives.  Dr. Allen has also taken on a personal goal to re-examine how clinical trials are being run for the development of therapies for chronic pain.  This initiative will reshape the way we conduct chronic pain trials, and how we think about and develop new therapies for these indications.

Dr. Allen has worked at Parke Davis, Pfizer, AstraZeneca, Wyeth Research, Premier CRO, Adolor, and Inventive / Syneos Health.  He has also been CEO of Allen Medical LLC for over the past ten years, and has served as CMO or acting CMO for 3 successful biotech start-ups, Afferent, Centrexion, and Concentric Pharmaceuticals.  

Prior to joining Industry, Dr. Allen worked in the Neuro-Oncology department at MD Anderson Cancer Center, and in the Neurology Department and Pain Center at the University of California, San Francisco. He completed a Pain Fellowship at UCSF, a Neurology Residency at The University of Michigan, and an Internal Medicine Residency at Faulkner Hospital in Boston. He earned his MD at Tufts Medical School in Boston, Massachusetts and his Undergraduate degree at Boston College.